Friday, December 27, 2013

A case where a state of New York took action against a compounding pharmacy for overbilling medicaid. Wonder how many other states should be taking similiar action?

A.G. Schneiderman Announces $100,000 Settlement With Pharmacy Owner For Overbilling Medicaid For Ketamine

Queens Pharmacy Overbilled Medicaid For Reimbursement For Larger Ketamine Dosages Than Those Used
Schneiderman: Settlement Holds Pharmacy Owner Accountable For Profiting At Taxpayers’ Expense
NEW YORK - Attorney General Eric T. Schneiderman announced today a $100,000 settlement with Oleg Aronov, a co-owner of Comprehensive Pharmacy, Inc. for overbilling taxpayers relating to the dispensation of compounded medications containing the drug Ketamine. Until its closing in 2009, Comprehensive Pharmacy was an enrolled provider of health care services to New Yorkers covered by Medicaid. Through its investigation, the Attorney General’s Office discovered that Comprehensive Pharmacy had overbilled Medicaid for Ketamine.
“Medical professionals who overbill Medicaid rob the program of important resources, and deprive many New Yorkers of essential services. This settlement holds Mr. Aronov accountable for profiting at the expense of taxpayers,” said Attorney General Schneiderman. “My office will remain committed to returning any funds misspent through violations of the Medicaid program.”
In addition to providing medications in the form of a pill or as a liquid, many pharmacies supply medications to patients in the form of creams. These compounded medications are usually prepared on site by a pharmacist. With regard to compounded medications containing Ketamine, Medicaid rules and regulations dictate that a provider may only seek reimbursement for the amount of Ketamine actually used in the compounded medication. Comprehensive Pharmacy, despite these rules, billed Medicaid as if Ketamine was the entire weight of the compound, when it was not. Attorney General Schneiderman’s investigation revealed that Comprehensive Pharmacy had submitted to the program tens of thousands of dollars in erroneous claims for compounded medications containing Ketamine.
Through his settlement with the Attorney General’s Office, Aronov agrees to reimburse the State, and admits to submitting erroneous claims to Medicaid indicating Comprehensive Pharmacy had dispensed compounded medications containing more Ketamine than was actually present in the medications dispensed to Medicaid patients.
While Ketamine, a general anesthesia, has a number of legitimate uses, it is also abused and is known as a “date rape” drug because of its ability to induce a dissociative state. Ketamine is classified as a Schedule III controlled substance. The Attorney General’s investigation did not uncover any evidence that the compounded medications prepared and erroneously billed by Comprehensive Pharmacy were being used for any illegal or illicit purposes.”
The Attorney General’s investigation originated from a referral by the New York State Office of the Medicaid Inspector General (OMIG). Attorney General Schneiderman would like to thank OMIG for its assistance in resolving this matter.
The case was handled by Deputy Regional Director Thomas O’Hanlon and Special Assistant Attorney General Samuel Yee, under the supervision of Assistant Deputy Attorney General Paul Mahoney and Special Deputy Attorney General Monica Hickey-Martin. The investigation was conducted by Senior Special Investigator Thomas Dowd, under the supervision of Chief Investigator Thaddeus Fischer, and by Special Auditor Investigator Olga Sunitsky, under the supervision of Supervising Special Auditor Emmanuel Archer and the Medicaid Fraud Control Unit’s New York City Regional Chief Auditor Thomasina Piccolo-Smith. 
A copy of today’s settlement can be found here: www.ag.ny.gov/pdfs/Oleg-2013.pdf

SAVE THE DATE: Don’t forget to mark your calendars for next year’s CASA Annual Educational and Training Seminar (ETS) (PDF). CASA will be hostingthe 98th Annual ETS in Grantville, PA just minutes away from Hershey, May 12-16, 2014. Topics include risk based inspections


Save the Date: The 2014 AFDOSS Spring Educational Conference - March 30-April 2, 2014 at the Hilton Garden Inn, Jackson/Downtown, Jackson, MS.


Fourteenth Question of the Day December 27, 2013 What other bulk drug substances besides those listed by the FDA/CVM are commonly used in compounded veterinary preparations?

APPENDIX A

LIST OF BULK DRUG SUBSTANCES FOR COMPOUNDING AND SUBSEQUENT USE IN ANIMALS TO WHICH CVM WOULD NOT ORDINARILY OBJECT
  • Ammonium molybdate
  • Ammonium tetrathiomolybdate
  • Ferric ferrocyanide
  • Methylene blue
  • Picrotoxin
  • Pilocarpine
  • Sodium nitrite
  • Sodium thiosulfate
  • Tannic acid
  • quoted from here

Thirteenth Question of the Day December 27, 2013 How many compounding pharmacies compound veterinary drugs in anticipation of receiving prescription, (except in very limited quantities) after receiving prescriptions issued within the confines of a valid Veterinary Client Relationship?


Twelfth Question of the Day December 27, 2013 How many veterinary drugs are compounded daily that are prohibited for extra-label use in food-producing or nonfood-producing animals, under 21 CFR 530.41 (a) and (b) respectively, because the drugs present a risk to the public health


Eleventh Question of the Day December 27, 2013 Who should establish withdrawal time the pharmacist or the prescribing veterinarian? Why?


Tenth Question of the Day December 27, 2013 How many veterinary compounding pharmacies use Inadequate labeling in that they do not have sufficient information, such as withdrawal times for drugs for food-producing animals or other categories of information that are described in 21 CFR 530.12 ?


Ninth Question of the Day December 27, 2013 How many compounding pharmacies compound veterinary preparations using commercial scale manufacturing equipment?


Nancy Tay, Accreditation Director National Association of Boards of Pharmacy--Discusses Iowa Inspections of Compounding Pharmacies

view powerpoint here

Save the Date: WAFDO 2014 Annual Educational Conference The WAFDO 2014 Annual Educational Conference will be a joint conference with AFDO and will be held the week of June 21 - 25, 2014 at the Grand Hyatt in Denver, Colorado


Pharmacy Compounding: FDA Regulatory Challenges Past, Current, Future Dennis E. Baker Regional Food and Drug Director Food and Drug Administration Southwest Region, Dallas, TX

Presentation done before DQSA but still very informative. To view powerpoint click here

Confounded in Compounding Apothecaries: The Critical Need for Confining State Pharmacy Boards to Self-Regulation BY WILLIAM G. SCHIFFBAUER

read here

Florida Board of Pharmacy Rule that became effective October 20, 2013 regarding compounding pharmacies

can be viewed here

Ninth Question of the Day December 27, 2013 How many compounded veterinary preparations are shipped to the United States each day?


Eighth Questionn of the Day December 27, 2013 Does the law prohibit a compounding pharmacy from offering free products with the purchase of every compounded preparation?


Seventh Question of the Day December 27, 2013 How many compounding pharmacists currently have specialized training, experience or education with regard to compounded veterinary preparations?


Sixth Question of the Day December 27, 2013 When will state veterinary medical boards hire inspectors knowledgeable about veterinary compounded preparations so that veterinary clinics and hospitals can be properly inspected for violations of the law?


Fifth Question of the Day December 27, 2013 When will state boards of pharmacy hire inspectors that are knowledgeable about veterinary preparations rather than just hiring pharmacists who know nothing about veterinary compounds?


Fourth Question of the Day December 27, 2013 What is the most illegal compounded veterinary preparation and what is it used for?


Third Question of the Day December 27, 2013 How can a compounded preparation be a decision between the doctor and the patient as ot what is best and necessary if the compounding pharmacy is the one doing the testing and recomendation for a compounded preparation such as a hormone?


Second Question of the Day December 27, 2013 How many veterinary only compounding pharmacies are there in the United States? Why would a compounding pharmacy choose to be veterinary only?


Question of the Day December 27, 2013 Is it legal for compounding pharmacies to have patients fill out questionaires and to test them for such things as hormone levels and then refer those patients to doctors (even if it is the patients own doctor) to write the prescription for the compounded preparations?


Complaint by Dr. Mark Sturdy v. AH Hauser for junk faxes

view here

Complaint filed by Insurance Company Against Speciality Pharmacy in Cedar Park TX

can be viewed here

FDA Starts Regulating Compounding Pharmacies Dec 27, 2013

The U.S. Food and Drug Administration on Monday began the process of regulating compounding pharmacies, which create new drug combinations or alter drugs to suit individual patient needs.
Under the Drug Quality and Security Act, signed into law Nov. 27 by President Barack Obama, these pharmacies are being encouraged to register with the FDA. The agency will then classify them as outsourcing pharmacies, enabling them to sell bulk drugs to hospitals and other health-care facilities.
The law was prompted by the deaths last year of 64 people who received fungus-contaminated steroid medications that were given in injections to treat back and joint pain. An additional 750 people in 20 states were sickened by the contaminated drug. The medication was made by the now-shuttered New England Compounding Center, in Framingham, Mass., according to federal health officials.
"The part of the law related to compounding is a step forward by creating a new pathway in which compoundersregister with FDA as an outsourcing facility," FDA commissioner Dr. Margaret Hamburg said during a Monday afternoon press briefing.
continue to read here

Enforcement Report - Week of December 26, 2013

Enforcement Report - Week of December 26, 2013

RMTC Tactical Research Program Identifies Substances in Roberson Case for Delaware Racing-HFL Sport Science -Lexington laboratory identified dichloracetic acid and tadalafil, which is marketed in the U.S. under the trade name Cialis™.

RMTC
NEWS RELEASE
October 17, 2013
Contact: Hallie Roach Lewis (859) 224-2848
RMTC TACTICAL RESEARCH PROGRAM IDENTIFIES SUBSTANCES IN ROBERSON CASE FOR DELAWARE RACING COMMISSION
The RMTC Tactical Research Program was instrumental in the Delaware Thoroughbred Racing Commission’s recent prosecution of Donald Roberson by working with the HFL Sport Science -Lexington laboratory to identify dichloracetic acid and tadalafil, which is marketed in the U.S. under the trade name Cialis™.
These substances were found during a July 13, 2013 search of Donald Roberson’s barn by the Delaware Thoroughbred Racing Commission that uncovered pre-loaded syringes with hypodermic needles attached and a large quantity of injectable substances. The injectable substances were compounded products labeled as GTO Accelerator and SK360. Samples of these two compounded substances were sent to the HFL Sport Science - Lexington laboratory as part of the RMTC’s Tactical Research Program.
Roberson received a two-year suspension and $2,500 fine – the maximum penalty that the stewards could impose. The Delaware Thoroughbred Racing Commission upheld the stewards ruling on October 16, 2013.

RMTC: Current Threshold Levels for Corticosteroids, Clenbuterol Should Remain 12/3/2013 RMTC


NEWS RELEASE
December 3, 2013
Contact: Hallie Roach Lewis (859) 224-2848
RMTC: CURRENT THRESHOLD LEVELS FOR CORTICOSTEROIDS, CLENBUTEROL SHOULD REMAIN
The Racing Medication & Testing Consortium (RMTC) is releasing two position papers which stated that no physiologic difference among the various racing breeds exists to justify changing regulatory thresholds from those recently established by the Racing Medication & Testing Consortium (RMTC) for the use of corticosteroids and clenbuterol.
The recommendations were made by a panel comprised of recognized laboratory directors, veterinary pharmacologists, practicing veterinarians, regulatory veterinarians, and veterinary surgeons with extensive experience in Thoroughbred, Standardbred, Quarter Horse and Arabian racing. The panel was established by the RMTC in response to a request by the United States Trotting Association (USTA) at the September 2013 RMTC board meeting to establish more liberal thresholds for the use of intra-articular corticosteroids and clenbuterol in the Standardbred breed.
The panel included the following individuals:
Rick Arthur, DVM – Equine Medical Director, California Horse Racing Board
Larry Bramlage, DVM, DACVS – Rood and Riddle Equine Hospital
Tom Brokken, DVM – Teigland, Franklin, and Brokken DVMs, PA
Lynn Hovda – RPH, DVM, MS, DACVIM – Chief Commission Veterinarian – Minnesota Racing Commission
Heather Knych, DVM, MS, PhD – University of California, Davis
Bobby Lewis, DVM – Elgin Veterinary Hospital
Wayne McIlwraith, BVSc, PhD, DACVS – Surgeon and Professor, Colorado State University
Paul Nolan, DVM – Equine Sports Medicine Associates
Mary Robinson, VMD, PhD – University of Pennsylvania School of Veterinary Medicine
Rick Sams, PhD – HFLSS-Lexington
Mary Scollay, DVM – Kentucky Horse Racing Commission
The Corticosteroid Position Paper outlines the concerns regarding both short term pain masking effects of corticosteroids as well as long term damage caused by injudicious use of these medications. The panel affirmed the thresholds originally proposed by the RMTC.
“The benefit of the intra-articular corticosteroid thresholds as enacted by RMTC is to allow sufficient time between treatment and racing to allow the veterinarian to evaluate the effects of such treatment,” stated panel member Dr. Wayne McIlwraith of Colorado State University. “Moreover, by providing a significant separation between intra-articular corticosteroid treatments and race-day, we minimize the potential for those treatments obscuring a more serious injury and compromising pre-race examinations.”
The Clenbuterol Position Paper provides a review of both the legitimate beneficial effects and potential integrity issues associated with clenbuterol use. Ultimately, the panel determined that the original threshold recommended by RMTC should be upheld.
“We believe that protecting the integrity of horse racing is paramount and, therefore, there should be a sufficient separation between the administration of clenbuterol and race day for all horses which is supported by the existing threshold,” stated RMTC board member and panel member Dr. Bobby Lewis. “We do, however, acknowledge the need to provide options to veterinarians that allow them to appropriately treat horses which is why we recommended researching albuterol and guaifenasin as alternative treatments to clenbuterol.”
Full copies of these documents are available at:
Clenbuterol Paper and Corticosteroids Paper.
The RMTC consists of 23 racing industry stakeholders and organizations that represent Thoroughbred, Standardbred, American Quarter Horse and Arabian racing. The organization works to develop and promote uniform rules, policies and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and protect the interests of the racing public.
For additional information, visit the RMTC website at rmtcnet.com or contact Hallie Lewis, RMTC director of communications, at (859) 224-2848.

New York Gaming Commission: The Commission has scheduled a rulemaking Public Hearing from 10:30 a.m. to 3:30 p.m. on Tuesday, January 21, 2014 in its sixth floor board room at One Broadway Center, Schenectady; in the meantime, it welcomes written comments.

The NY State Gaming Commission has proposed five amendments to its Thoroughbred equine drug rules to create per se thresholds for 24 drugs and medications, make it a rule violation if the Commission’s laboratory can detect by testing race. see more

Maryland Racing Commission takes steps on medication rules that will become effective 1/1/2014

by Frank Vespe
With the clock ticking towards the January 1 adoption of new medication rules in Maryland, the state Racing Commission today engaged in a vigorous — and occasionally odd and contentious — discussion about them.
Communism, polygraph tests, and personal affronts all made appearances during a wide-ranging debate.
While much public attention has focused on the new list of 24 permitted medications, threshold levels, and withdrawal times, one area that has concerned many horsemen is the new Lasix policy that will require a third-party veterinarian to administer the anti-bleeder medication.  That policy is in contrast to long-standing rules that allow vets to administer the drug to the horses under their day-to-day care.
The Commission voted today to award that contract to Dr. Jay Baldwin, a veterinarian who administers similar contracts at Delaware Park and Penn National, as well as several harness tracks.  He told the Commission that his team was “experienced, reliable, and honest” and that the people he hires are “beyond reproach.”
continue to read here

REFORMED RACING MEDICATION RULES Recommended by the Jockey Club

REFORMED RACING MEDICATION RULES -To bring forward much-needed uniformity to the medication rules and penalties in horse racing, there needs to be a streamlined set of regulations that is on par with international standards and creates a new enforcement scheme with stronger penalties and deterrents. The adoption of The Reformed Racing Medication Rules would do just that.


  • Horses should be allowed to compete only when free from the influences of medication
  • Medications permitted in the race horse are subjected to stricter regulatory thresholds with increased recommended withdrawal times
  • Only RMTC-accredited laboratories are to be permitted to test samples, with results available to the public
  • Medication violations result in points that accumulate to trigger stronger sanctions for repeat violations; up to lifetime suspensions
  • Medication histories for all horses available for review
  • Contact with a horse within 24 hours of post time of the race shall be subject to surveillance; certain regulations and track ship-in policies may be subject to adjustment
  • Expansion of regulatory authority to include all jurisdictions where official "workouts" are conducted
  • Administration and withdrawal guidelines are published for all approved therapeutic medication subject to regulatory control
  • Best practices for improved security and monitoring of "in today" horses are provided for guidance to racing associations

Thursday, December 26, 2013

Texas Racing Commission issued new Clenbuterol thresholds that went into effect in 2013

Alert - New Clenbuterol thresholds went into effect March 28, 2013.

quoted from here

Texas Racing Commission Discussed Recent Inspections, Enforcement Report and Veterinary, and Adoption of Amendment to Rule 319.3, Medication Restricted at December 2013 Meeting

agenda can be viewed here and transcript of the meeting here

CHAPTER 319. VETERINARY PRACTICES AND DRUG TESTING
SUBCHAPTER A. GENERAL PROVISIONS


Sec. 319.3. Medication Restricted
(a) Except as otherwise provided by this section, a horse or
greyhound participating in a race may not carry in its body a
prohibited drug, chemical, or other substance.
[(b) The maximum permissible plasma or serum concentration of 
phenylbutazone in horses is 2.0 micrograms per milliliter.] 
(b)[(c)] Furosemide at or below the approved tolerance level in
a horse that has been admitted to the furosemide program is
permissible. The approved tolerance level shall be published on
the list of therapeutic drugs posted under subsection (c)[(d)]
of this section.
(c)[(d)] Levels [Trace levels] of drugs which are therapeutic
and necessary for treatment of illness or injury in race animals
are permissible, provided:
(1) the therapeutic drug is on a written list approved by
the executive secretary, maintained by the commission
veterinarian, and posted in the commission veterinarians'
office; and
(2) the maximum permissible urine or blood concentration of
the drug does not exceed the published limit, if any, on the
written list of therapeutic drugs.
(d)[(e)] Except as otherwise provided by this chapter, a person
may not administer or cause to be administered to a horse or
greyhound a prohibited drug, chemical, or other substance, by
injection, by oral or topical administration, by rectal infusion
or suppository, by nasogastric intubation, or by inhalation, and
any other means during the 24-hour period before the post time
for the race in which the animal is entered.
(e)[(f)] A positive finding by a chemist of a prohibited drug,
chemical, or other substance in a test specimen of a horse or
greyhound collected before or after the running of a race,
subject to the rules of the commission relating to split
specimens, is prima facie evidence that the prohibited drug,
chemical, or other substance was administered to the animal and
was carried in the body of the animal while participating in a
race.

Feds: Pharmacy owner charged in prescription drug fraud scheme

Originally published: December 13, 2013 7:01 PM
Updated: December 13, 2013 7:18 PM
By ELLEN YAN  ellen.yan@newsday.com
A Port Washington man who runs two New York City pharmaciessold secondhand prescription drugs as "factory fresh" from legitimate suppliers in a scam to defraud government health programs out of millions of dollars, federal authorities said Friday.
Purna Chandra Aramalla, 65, has been held on a $2 million bond since his arraignment Tuesday on one count of conspiracy to commit health care fraud and wire fraud and one count of moneylaundering, said the U.S. attorney in Manhattan and the FBI. He faces up to 20 years on each count.
Aramalla would order certain expensive, brand-name drugs, such as HIV medicines, from a street supplier who'd get them from patients who didn't want to take their medicine, federal officials said.
continue to read here

Compounding Pharmacy Tech W/Expirience Jamaica, NY

Jamaica, NY (16 miles from Staten Island, New York) 
Specialty Compounding Pharmacy is looking for a highly motivated person to fill the PHARMACY COMPOUNDING TECHNICIAN WITH EXPERIENCE position with us for long term. Important to be mature, have...
12/26/2013

Harris Beach attorney Frederick H. Fern is presenting on compounding pharmacy at the 2014 New York State Bar Association Annual Meeting on January 30, 2014 at the Hilton, New York Midtown.

more information found here

SALES REP -- COMPOUNDED RX INDUSTRY - $8K TO $15K REALISTIC MONTHLY (Ventura County)

SALES REP -- COMPOUNDED RX INDUSTRY - $8K TO $15K REALISTIC MONTHLY (Ventura County)

SALES REP -- COMPOUNDED RX INDUSTRY - $8K TO $15K REALISTIC MONTHLY -- COMMISSION & BONUS COMPENSATION OPPORTUNITIES
Here is your chance to join a fast-growing business in the medical/pharma industry focusing on the dispensing of topical compounded Rx medications by physicians and surgeons via a compounding pharmacy. We are seeking qualified Sales Reps/Account Executives whose duties primarily are focused on the acquisition of new accounts and the maximization of current accounts.
Compensation is commission-based. Our current sales group make from $8K TO $15k+ monthly within 60 days with us. This is an extremely exciting and fast paced work environment.
There is room for professional growth and the possibility for you to manage others with bonus override compensation paid to you in addition to your own commission based compensation.
You will receive comprehensive training and industry leading commission compensation. You can achieve your monthly earnings goals with as few as a half dozen regularly dispensing clients in your territory.
There are opportunities for additional bonuses for achieving and exceeding your territory goals on top of base commission.
This position can be an excellent opportunity to add additional income if you are currently a sales rep and have a base of physicians. The best specialties include but are not limited to Orthopedics, Pain Management, Podiatry, Internal Medicine, Family Practice, ENT, Dentists and Dental Surgeons, and Plastic Surgeons to name a few.
Here are the requirements for this sales position:

-Minimum 2 years' experience in medical sales facing off with physician practitioners in their offices
-Strong phone and interpersonal skills
-Closer mentality
-Driven personality to earn $150K+ in the first year with the company
-Open to managing other Sales Reps/Account Executives
-Open to additional products to market as time dictates

The benefits of working with us include:

-High level of independence while focusing on your sales goals in your territory
-Exclusive territory assignment and territory protection with the achievement of minimum quarterly sales goals
-Management of up to 3 additional Sales Reps/Account Executives after 90 days of employment and of achieving sales goals in your primary territory
-President Club bonuses and annual trip opportunities for the top achievers
-Part of your compensation package is available for weekly payment based upon meeting certain criteria (we will share more with you at a later date)
-Group health insurance plan participation after 60 days of employment and achieving minimum sales goals in your primary territory
-Auto reimbursement and mobile phone reimbursement after 60 days of employment and achieving minimum sales goals for your primary territory while maintaining minimum sales goals thereafter

Please email your CV to us at CompoundedMeds@ aol.com for immediate consideration. Start your new sales position as early as next week.

We look forward to hearing from you and the start of an exciting rewarding career with us.

Happy Holidays to you and your family. 
  • Location: Ventura County
  • Compensation: Commission, Bonuses, and Overrides
  • Telecommuting is ok.
  • Principals only. Recruiters, please don't contact this job poster.
  • do NOT contact us with unsolicited services or offers

Comments on problems with complying with California Board of Pharmacy laws relating to compounding

You will want to read Jerry Fahrni's blog comments regarding California's laws relating to compounding found here.  In his opinion, the two sections that are going to create the most havoc in pharmacies are CCR 1735.2 and CCR 1735.3.

FDA Warns of Supplement Containing Steroid By Sean Patterson · 6 hours ago · Posted in the Science Channel

The U.S. Food and Drug Administration (FDA) this week warned consumers against a dietary supplement named Mass Destruction. The bodybuilding supplement has been found to contain a synthetic anabolic steroid.
The FDA warning came on the heels of a death that is being blamed on the product. According to the North Carolina Department of Health and Human Services, a 28-year-old man was seriously injured by Mass Destruction. After using the supplement for what the FDA calls “several weeks” the man required a liver transplant due to liver failure.
According to the FDA, liver injury is a known possible side-effect of steroid use. Other side effects of steroid abuse include testicle shrinkage, infertility, breast enlargement, and increased risks for heart attack and stroke.
continue to read here

FDA moves timidly against antibiotic use on farms: Our view The Editorial Board, USATODAY 7:43 p.m. EST December 25, 2013 Spread of drug-resistant bugs requires more aggressive action.

read here

Admiral Insurance Company has sued Specialty Compounding, LLC over insurance coverage

U.S. District Court [LIVE]
Western District of Texas (Austin)
CIVIL DOCKET FOR CASE #: 1:13-cv-01077-LY


Admiral Insurance Company v. Specialty Compounding, LLC
Assigned to: Judge Lee Yeakel
Demand: $75,001,000
Cause: 28:1332 Diversity-Insurance Contract

Date Filed: 12/19/2013
Jury Demand: Plaintiff
Nature of Suit: 110 Insurance
Jurisdiction: Diversity
Plaintiff
Admiral Insurance Companyrepresented byGreg C. Wilkins 
Orgain Bell & Tucker LLP
P.O. Box 1751
Beaumont, TX 77704-1751
(409) 838-6412
Fax: (409) 838-6959
Email: gcw@obt.com
ATTORNEY TO BE NOTICED

V.
Defendant
Specialty Compounding, LLC

Date Filed#Docket Text
12/19/20131 COMPLAINT ( Filing fee $ 400 receipt number 0542-6109732). No Summons requested at this time, filed by Admiral Insurance Company. (Attachments: # 1 Civil Cover Sheet)(Wilkins, Greg) (Entered: 12/19/2013)
12/19/20132 RULE 7 DISCLOSURE STATEMENT filed by Admiral Insurance Company. (Wilkins, Greg) (Entered: 12/19/2013)
12/19/2013 Case Assigned to Judge Lee Yeakel. CM WILL NOW REFLECT THE JUDGE INITIALS AS PART OF THE CASE NUMBER. PLEASE APPEND THESE JUDGE INITIALS TO THE CASE NUMBER ON EACH DOCUMENT THAT YOU FILE IN THIS CASE. (td) (Entered: 12/19/2013)

Dr. Mark Sturdy d/b/a Rochester Veterinary Clinic has sued A.F. Hauser, Inc. for Fax Advertisements

U.S. District Court
CENTRAL DISTRICT OF ILLINOIS (Springfield)
CIVIL DOCKET FOR CASE #: 3:13-cv-03379-CSB-DGB


Dr. Mark W. Sturdy v. A. F. Hauser, Inc. et al
Assigned to: Judge Colin Stirling Bruce
Referred to: Magistrate Judge David G. Bernthal
Cause: 47:227 Telephone Consumer Protection Act

Date Filed: 11/11/2013
Jury Demand: None
Nature of Suit: 890 Other Statutory Actions
Jurisdiction: Federal Question
Plaintiff
Dr Mark W Sturdy
on behalf of plaintiff and class members defined herein
doing business as
Rochester Veterinary Clinic
represented byDulijaza Julie Clark 
EDELMAN COMBS LATTURNER & GOODWIN LLC
Suite 1800
120 S LaSalle St
Chicago, IL 60603
(312)739-4200
Fax: 419-0379
Email: jclark@edcombs.com
ATTORNEY TO BE NOTICED

Michelle R Teggelaar 
EDELMAN COMBS LATTURNER & GOODWIN LLC
Suite 1800
120 S LaSalle St
Chicago, IL 60603
312-739-4200
Fax: 419-0379
Email: mteggelaar@edcombs.com
ATTORNEY TO BE NOTICED

Daniel A Edelman 
EDELMAN COMBS LATTURNER & GOODWIN LLC
Suite 1800
120 S LaSalle St
Chicago, IL 60603
312-739-4200
Fax: 312-419-0379
Email: courtecl@edcombs.com
ATTORNEY TO BE NOTICED

V.
Defendant
A. F. Hauser, Inc.
Defendant
John Does 1-10

Pegasus Laboratories, Inc. v. Weatherford Compounding Pharmacy Assigned to: District Judge Carlos Murguia Referred to: Magistrate Judge K. Gary Sebelius Cause: 35:145 Patent Infringement Is Still Pending: Weatherford Compounding Pharmacy has Until 1/10/2014 to Respond

12/20/2013ORDER granting 8 Agreed Motion for Extension of Time to Answer. Defendant Weatherford Compounding Pharmacy shall answer or otherwise respond to plaintiff's complaint by 1/10/2014. Signed by Magistrate Judge K. Gary Sebelius on 12/20/2013. (This is a TEXT ENTRY ONLY. There is no.pdf document associated with this entry.) (bh) (Entered: 12/20/2013)

Case against Diamondback Drugs, LLC for Patent Infringement filed by Pegasus Laboratories was dismissed

U.S. District Court
DISTRICT OF KANSAS (Kansas City)
CIVIL DOCKET FOR CASE #: 2:13-cv-02334-EFM-GLR


Pegasus Laboratories, Inc. v. Diamondback Drugs, LLC
Assigned to: District Judge Eric F. Melgren
Referred to: Magistrate Judge Gerald L. Rushfelt
Cause: 35:145 Patent Infringement

Date Filed: 07/10/2013
Date Terminated: 11/20/2013
Jury Demand: Plaintiff
Nature of Suit: 830 Patent
Jurisdiction: Federal Question
Plaintiff
Pegasus Laboratories, Inc.represented byRobert C. Garrison 
Lathrop & Gage, LLP - KC
2345 Grand Boulevard, Suite 2200
Kansas City, MO 64108-2618
816-292-2000
Fax: 816-292-2001
Email: cgarrison@lathropgage.com
LEAD ATTORNEY
ATTORNEY TO BE NOTICED

V.
Defendant
Diamondback Drugs, LLC

Date Filed#Docket Text
07/10/20131 COMPLAINT (No Summons Issued) with trial location of Kansas City, filed by Pegasus Laboratories, Inc. (ta) (Entered: 07/10/2013)
07/10/20132 CIVIL COVER SHEET re: 1 Complaint by Plaintiff Pegasus Laboratories, Inc. (ta) (Entered: 07/10/2013)
07/10/20133 DESIGNATION OF PLACE OF TRIAL filed by Plaintiff Pegasus Laboratories, Inc. - trial to be held in Kansas City. (ta) (Entered: 07/10/2013)
07/10/2013 FILING FEE PAID: in the amount of $400.00, receipt number K4631039367. (ta) (Entered: 07/10/2013)
07/10/20134 AO FORM 120: REPORT on the Filing or Determination of an Action Regarding a Patent or Trademark. (Attachments: # 1 Complaint and Exhibits) (ta) (Entered: 07/10/2013)
11/05/2013 SUMMONS ISSUED as to Diamondback Drugs, LLC. Summons issued and emailed to Plaintiff's Attorney for service. (This is a TEXT ENTRY ONLY. There is no.pdf document associated with this entry.) (ta) (Entered: 11/05/2013)
11/20/20135 NOTICE OF VOLUNTARY DISMISSAL by Pegasus Laboratories, Inc. Without Prejudice. (Garrison, Robert) (Entered: 11/20/2013)
11/20/2013 ***Civil Case Terminated. See 5 Voluntary Dismissal Without Prejudice pursuant to Fed. R. Civ. P. 41(a)(1). (mg) (Entered: 11/21/2013)

The Drug Quality and Security Act — Mind the Gaps Kevin Outterson, J.D., LL.M

read here

Wednesday, December 25, 2013

Webcast: Compounding pharmacy regulations, state's IT struggles Editorial page editor Ted Rayburn and columnist Frank Daniels III discuss the Tennessean's editorial calling for more meaningful compounding pharmacy regulations and the state of Tennessee's struggles with information technology.

VIEW VIDEO HERE

Staff Writer Fred Hiers talks about reporting and writing about the compounding industry for his series in Ocala Star-Banner

view video here

Congress acts, but meningitis patients' pain lingers in 2013 Physical and financial challenges continue to take toll Dec. 25, 2013 2:53 AM

Written by
Wayne Peal
Daily Press & Argus

The past year brought continuing challenges, both physically and financially, for the hundreds of fungal meningitis patients across the country — including those in Livingston County.
“It’s very discouraging and depressing,” Evelyn Bates-March of Hamburg Township said of her long-running battle with the infection.
It also brought a sign that the federal government had gotten serious about the problems which led to the man-made outbreak.
Even that is subject to question as the outbreak enters its second full year.
The outbreak has been linked to contaminated steroid solutions mixed at a now-closed Massachusetts compounding center.
Patients enter the new year eagerly awaiting the outcome of court action against the New England Compounding Center.
continue to read here

Tuesday, December 24, 2013

FDA warns against using Mass Destruction

12/23/2013 02:46 PM EST

The U.S. Food and Drug Administration is advising consumers to immediately stop using a product called Mass Destruction, marketed as a dietary supplement for muscle growth. The product is labeled to contain at least one synthetic anabolic steroid and has been linked to at least one reported serious illness.